bladder cancer
Conditions
Interventions
Case series:No
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 78 Years
Inclusion criteria
Inclusion criteria: Patients must meet all of the following inclusion criteria to be included in this study: 1. Age range: 18-78 years old; 2. The patient must have histologically confirmed muscle infiltrating bladder urothelial carcinoma, which has been clinically determined as cT2-T4a, N0, M0 based on imaging evaluation; 3. The physical condition (PS) score of the Eastern Cooperative Oncology Group (ECOG) is 0 or 1; 4. Life expectancy >= 10 years; 5. Patients who choose radical cystectomy as the main treatment for muscle invasive bladder urothelial carcinoma; 6. Normal liver function: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 35g, no ascites or hepatic encephalopathy; 7. Normal coagulation function: INR = 50%; QTc= 60 mL/min; 10. The ability of the subjects to understand and be willing to sign informed consent forms; Be able to comply with research visit schedules and other protocol requirements.
Exclusion criteria
Exclusion criteria: Patients with any of the following conditions are not eligible for inclusion in this study: 1. There are other malignant tumors present; 2. Previous experiences include immunotherapy, targeted therapy, platinum chemotherapy (such as cisplatin, carboplatin, or others), as well as other chemotherapy and radiotherapy; 3. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related diseases, active or symptomatic viral hepatitis or chronic liver disease; 4. Clinically significant heart diseases, such as NYHA III-IV heart failure, myocardial infarction, or arterial thrombosis events in the past 6 months, severe or unstable angina, or recent ventricular arrhythmias; 5. Pituitary dysfunction and adrenal cortex dysfunction; 6. Uncontrollable severe hypertension, hypokalemia, water and sodium retention; 7. Pre existing duodenal stents and/or any gastrointestinal diseases or defects that researchers believe may interfere with drug absorption; 8. Allergic to neoadjuvant drugs or other contraindications to use; The researcher considers it inappropriate to participate in this clinical trial for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathologic complete response; | — |
Secondary
| Measure | Time frame |
|---|---|
| The impact of neoadjuvant therapy on surgery;Safety within 90 days after neoadjuvant therapy surgery;Safety during neoadjuvant therapy; | — |
Countries
China
Contacts
Public ContactHongzhao Li
Department of Urology, Chinese PLA General Hospital
Outcome results
None listed